# Bernard-Soulier {-}

## **Overview of Bernard-Soulier Syndrome (BSS)** {-}

*   **Definition:** A rare, inherited bleeding disorder characterized by:
    *   Thrombocytopenia (low platelet count)
    *   Giant platelets (macrothrombocytes)
    *   Dysfunctional platelet adhesion
*   **Genetic Basis:** Autosomal recessive inheritance of mutations in genes encoding components of the platelet glycoprotein Ib/IX/V (GPIb/IX/V) complex
*   **Key Feature:** Impaired platelet adhesion to damaged blood vessel walls due to a defect in the GPIb/IX/V receptor
*   **Clinical Significance:** Leads to mucocutaneous bleeding tendencies, such as easy bruising, nosebleeds, and prolonged bleeding after trauma or surgery

## **Platelet Glycoprotein Ib/IX/V (GPIb/IX/V) Complex** {-}

*   **Structure:** A complex of four transmembrane glycoproteins:
    *   GPIbα: The primary vWF-binding subunit
    *   GPIbβ
    *   GPIX
    *   GPV
*   **Function:**
    *   Mediates the initial adhesion of platelets to damaged blood vessel walls by binding to von Willebrand factor (vWF)
    *   This interaction is essential for platelet plug formation, especially under high shear stress conditions
    *   Also involved in platelet signaling and activation

**Pathophysiology of Bernard-Soulier Syndrome** {-}

*   **Genetic Mutations:** Mutations in genes encoding GPIbα (CD42b), GPIbβ (CD42c), or GPIX (CD42a) lead to:
    *   Decreased expression of the GPIb/IX/V complex on the platelet surface
    *   Abnormal structure or function of the GPIb/IX/V complex
*   **Impaired Platelet Adhesion:**
    *   Defective GPIb/IX/V complex impairs platelet adhesion to vWF, particularly under high shear stress conditions
    *   This impairs the ability of platelets to form a stable plug at sites of vascular injury, leading to a prolonged bleeding time
*   **Macrothrombocytopenia:**
    *   Megakaryocytes in the bone marrow may be enlarged and have abnormal morphology due to impaired platelet shedding
    *   The released platelets are often abnormally large (macrothrombocytes)

## **Clinical Features** {-}

*   **Bleeding Manifestations:** Severity varies, but most patients have moderate to severe mucocutaneous bleeding:
    *   Easy bruising
    *   Nosebleeds (epistaxis)
    *   Gum bleeding
    *   Prolonged bleeding after minor cuts or dental procedures
    *   Menorrhagia (heavy menstrual bleeding) in women
    *   Gastrointestinal bleeding (less common)
*   **Splenomegaly:** Enlargement of the spleen may be present in some cases
*   **Thrombocytopenia:** Platelet counts are often mildly to moderately decreased, but can be normal in some cases

## **Laboratory Findings** {-}

*   **Complete Blood Count (CBC):**

    *   Platelet count: Often mildly decreased (thrombocytopenia), typically in the range of 50-150 x 10^9/L, but can be normal in some cases
    *   RBC and WBC counts: Usually normal

*   **Peripheral Blood Smear:**

    *   Macrothrombocytes (Giant Platelets):
        *   Characteristically large platelets (often as large as or larger than red blood cells)
        *   Essential for diagnosis
    *   Decreased platelet number

*   **Bleeding Time:**

    *   Prolonged (often significantly prolonged)
    *   *Note:* The bleeding time is not a very specific or sensitive test and is rarely used now. PFA testing has taken its place.

*   **Platelet Function Analyzer (PFA-100):**

    *   Prolonged closure time with both epinephrine and ADP cartridges
    *   Suggests a platelet adhesion defect

*   **Platelet Aggregation Studies:**

    *   Normal Aggregation with ADP, Collagen, and Epinephrine
    *   These agonists stimulate platelet aggregation via pathways *independent* of GPIb/IX/V
    *   Absent Aggregation with Ristocetin
        *   Ristocetin requires vWF and GPIb/IX/V to cause platelet aggregation
        *   *Even with the addition of normal plasma (to provide vWF), aggregation remains absent*

*   **Flow Cytometry Immunophenotyping:**

    *   Decreased or Absent Expression of GPIbα (CD42b), GPIbβ (CD42c), and GPIX (CD42a) on Platelets
        *   This confirms the defect in the GPIb/IX/V complex
        *   Essential for definitive diagnosis

## **Diagnostic Approach** {-}

1.  **Suspect BSS:** In a patient with:
    *   History of mucocutaneous bleeding
    *   Thrombocytopenia
    *   Large platelets on peripheral blood smear
2.  **Perform Platelet Aggregation Studies:** Absent ristocetin-induced platelet aggregation that is *not* corrected by the addition of normal plasma is a key finding
3.  **Confirm Diagnosis with Flow Cytometry:** Demonstrate decreased or absent expression of GPIbα, GPIbβ, and GPIX on platelets
4.  **Rule Out Other Causes of Thrombocytopenia with Giant Platelets:**
    *   May-Hegglin Anomaly: Döhle bodies in neutrophils, normal GPIb/IX/V expression
    *   Gray Platelet Syndrome: Alpha-granule deficiency, normal GPIb/IX/V expression
    *   Inherited thrombocytopenias (e.g., Wiskott-Aldrich syndrome, MYH9-related disorders): Variable clinical features and lab findings

## **Treatment and Management** {-}

*   **No Specific Cure:** Treatment is primarily supportive
*   **Avoid Aspirin and NSAIDs:** These medications can further impair platelet function and increase the risk of bleeding
*   **Minimize Trauma:** Avoid activities that could lead to injury
*   **Platelet Transfusions:**

    *   Used to treat significant bleeding episodes or before surgery
    *   Patients may develop alloantibodies (antibodies against foreign platelets) with repeated transfusions, making subsequent transfusions less effective
    *   HLA-matched platelets may be required in patients who have become alloimmunized
*   **Recombinant Factor VIIa (rFVIIa):**

    *   May be used to control bleeding in some patients with BSS
    *   Mechanism of action is not fully understood
*   **Antifibrinolytic Agents:**

    *   Tranexamic acid or aminocaproic acid may be used to control mucosal bleeding (e.g., nosebleeds, menorrhagia)
    *   These medications inhibit fibrinolysis (the breakdown of blood clots)
*   **Hematopoietic Stem Cell Transplantation (HSCT):**

    *   Potentially curative option for severe cases of BSS
    *   Involves replacing the patient's damaged bone marrow with healthy stem cells from a donor

## **Key Terms** {-}

*   **Bernard-Soulier Syndrome (BSS):** Rare inherited bleeding disorder characterized by thrombocytopenia, giant platelets, and dysfunctional platelet adhesion
*   **GPIb/IX/V:** Platelet glycoprotein receptor for von Willebrand factor (vWF)
*   **Macrothrombocytes:** Abnormally large platelets
*   **Ristocetin:** An antibiotic that induces vWF-dependent platelet agglutination
*   **Platelet Aggregation Studies:** Tests that measure the ability of platelets to clump together
*   **Flow Cytometry:** Technique to identify cell surface markers
*   **Alloantibodies:** Antibodies against foreign antigens (e.g., transfused platelets)
